DE60012961T2 - Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion - Google Patents

Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion Download PDF

Info

Publication number
DE60012961T2
DE60012961T2 DE60012961T DE60012961T DE60012961T2 DE 60012961 T2 DE60012961 T2 DE 60012961T2 DE 60012961 T DE60012961 T DE 60012961T DE 60012961 T DE60012961 T DE 60012961T DE 60012961 T2 DE60012961 T2 DE 60012961T2
Authority
DE
Germany
Prior art keywords
active ingredient
combination
entecavir
bms
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60012961T
Other languages
German (de)
English (en)
Other versions
DE60012961D1 (de
Inventor
A. Nathaniel BROWN
D. Lynn CONDREAY
Fraser Douglas GRAY
Marc Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60012961D1 publication Critical patent/DE60012961D1/de
Publication of DE60012961T2 publication Critical patent/DE60012961T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60012961T 1999-10-29 2000-10-27 Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion Expired - Lifetime DE60012961T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US429863 1995-04-27
US09/429,863 US6432966B2 (en) 1999-10-29 1999-10-29 Antiviral combinations
PCT/GB2000/004137 WO2001030329A2 (en) 1999-10-29 2000-10-27 Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction

Publications (2)

Publication Number Publication Date
DE60012961D1 DE60012961D1 (de) 2004-09-16
DE60012961T2 true DE60012961T2 (de) 2005-08-18

Family

ID=23705033

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60012961T Expired - Lifetime DE60012961T2 (de) 1999-10-29 2000-10-27 Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion

Country Status (10)

Country Link
US (1) US6432966B2 (cg-RX-API-DMAC7.html)
EP (1) EP1225904B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003512421A (cg-RX-API-DMAC7.html)
AR (1) AR026255A1 (cg-RX-API-DMAC7.html)
AT (1) ATE273012T1 (cg-RX-API-DMAC7.html)
AU (1) AU1042701A (cg-RX-API-DMAC7.html)
DE (1) DE60012961T2 (cg-RX-API-DMAC7.html)
ES (1) ES2225245T3 (cg-RX-API-DMAC7.html)
TW (1) TWI282735B (cg-RX-API-DMAC7.html)
WO (1) WO2001030329A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001229775A1 (en) * 2000-02-29 2001-09-12 Bristol-Myers Squibb Company Low dose entecavir formulation and use
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US8168568B1 (en) * 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1抗原決定位胜肽及含此胜肽的疫苗
CN102552210B (zh) * 2012-01-10 2013-12-11 四川海思科制药有限公司 一种恩替卡韦胶囊组合物及其制备方法
KR20170132327A (ko) * 2015-04-07 2017-12-01 스프링 뱅크 파마슈티칼스, 인크. Hbv 감염의 치료를 위한 조성물 및 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800452D0 (sv) * 1998-02-13 1998-02-13 Medivir Ab Antivirals
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
ATE131730T1 (de) 1991-05-16 1996-01-15 Glaxo Group Ltd Nukleosidanalogen enthaltende antiviren- zubereitungen
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
EP0988042B1 (en) * 1997-04-15 2008-01-09 Advanced Viral Research Corp. Combination of product r and an antiviral agent in the therapy of hiv infections
AU738472B2 (en) * 1997-09-25 2001-09-20 Cornell Research Foundation Inc. Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection

Also Published As

Publication number Publication date
DE60012961D1 (de) 2004-09-16
EP1225904A2 (en) 2002-07-31
ATE273012T1 (de) 2004-08-15
ES2225245T3 (es) 2005-03-16
US20020002180A1 (en) 2002-01-03
TWI282735B (en) 2007-06-21
EP1225904B1 (en) 2004-08-11
AR026255A1 (es) 2003-02-05
JP2003512421A (ja) 2003-04-02
US6432966B2 (en) 2002-08-13
WO2001030329A2 (en) 2001-05-03
AU1042701A (en) 2001-05-08
WO2001030329A3 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
DE69622386T2 (de) Synergistische kombinationen von zidovudine, 1592u89 und 3tc
DE60020820T2 (de) Thiadiazolyl-harnstoffe oder -thioharnstoffe zur antiviralen behandlung
DE69230140T2 (de) Antivirale nucleosidkombination
DE69318031T2 (de) Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung
DE69201948T2 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
DE60318192T2 (de) Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
DE60206775T2 (de) Agonisten für den adenosin a3 rezeptor
DE69932154T2 (de) Verwendung von n-substituirten-1,5-dideoxy-1,5-imino-d-glucitolen zur behandlung von hepatitis infektionen
DE69313872T2 (de) Verbindung von nucleocidanaloga zur behandlung viraler infektionen
DE3876174T2 (de) 2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirus-infektionen.
WO2001045712A1 (de) Arzneimittelkombinationen gegen virale erkrankungen
DE69527294T2 (de) 4-[2-amino-6-(cyclopropylamino)-9h-pyrin-9-yl]-2-cyclopenten-1-methanol-succinat als antivirales mittel
DE60021065T2 (de) Virus behandlung
DE69031340T2 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
DE69918447T2 (de) Antivirale kombinationen von lamivudin und adefovir
EP0038438A2 (de) Substituierte 1,2,5-Oxadiazol-2-oxide zur Anwendung als Arzneimittel und sie enthaltende Arzneimittel
EP0374096A1 (de) 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
DE69912842T2 (de) Antivirale nukleosidanaloga
DE69923338T2 (de) Kombinationstherapie zur behandlung von hepatitis b infektionen
EP1225904B1 (en) Combinations of lamivudine and entecavir for treatment of hepatitis b virus infection
DE10030781A1 (de) Kombinationspräparate von 3-N-Formylhydroxylaminopropylphosphonsäurederivaten oder 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten mit spezielen pharmazeutischen Wirkstoffen
DE60011060T2 (de) Virus behandlung
DE69718168T2 (de) Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
DE3780343T2 (de) Antivirale 8-phenylxanthine.
DE60319211T2 (de) Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition